Among all patients receiving gilteritinib (n = 108), CR rates with prior AML therapy were higher among patients with FLT3‐ITD mutation clearance (80%; n = 8/10) than in those without FLT3‐ITD mutation clearance (58%; n = 57/98), and the median duration of CR achieved with prior AML therapy was also longer in patients with FLT3‐ITD mutation clearance (7.9 vs. 4.1 months, respectively). This evidence concerns the gene FLT3 and acute myeloid leukemia.